CEA is currently employed as a routine marker for CRC prognosis, disease-free survival and therapeutic response [40] and as an independent predictor of patients at higher risk of CRC recurrence and/or metastases during postoperative follow-up [41]. The gene discussed is CEACAM5; the disease is colorectal carcinoma.